Accordingly, our group recently demonstrated that the use of NY-ESO-1157–165 HLA-A*02:01-specific TCR-T cells against decitabine-induced AML efficiently lysed AML cell lines and primary AML blasts and targeted AML in a xenograft model (data not shown). The gene discussed is HLA-A; the disease is acute myeloid leukemia.